Eyepoint (EYPT) closed at $0.40 on November 10, 2026, up 11.6% from the previous close, on volume of 4,276,811 shares (30-day average 12,885,296).
Data as of November 10, 2026.
| # | Date | Strategy | Legs | Contracts | Position |
|---|---|---|---|---|---|
| 1 | Oct 14, 2026 | Calendar Put Spread | 20-Nov : 18-Dec-26 4 P | 800 |
Ranked by contracts: multi-leg trades of 200 or more contracts on one day, through Nov 10, 2026. See the 10 largest for 30, 60 and 90 days
EyePoint Announces Participation at Upcoming Investor Conferences and Scientific Meetings
Globe Newswire (Fri, 6-Nov 7:00 AM ET)
EyePoint to Report Third Quarter 2026 Financial Results on November 12, 2026
Globe Newswire (Thu, 5-Nov 7:00 AM ET)
Globe Newswire (Tue, 3-Nov 5:46 PM ET)
EyePoint Pharmaceuticals (EYPT) Securities Investigation Notice - Levi & Korsinsky
Globe Newswire (Mon, 26-Oct 11:46 AM ET)
Globe Newswire (Thu, 22-Oct 10:15 AM ET)
ACCESS Newswire (Wed, 21-Oct 10:10 AM ET)
PRNewswire (Tue, 20-Oct 10:10 AM ET)
PRNewswire (Mon, 19-Oct 5:59 PM ET)
EyePoint Announces Strategic Prioritization
Globe Newswire (Mon, 19-Oct 7:15 AM ET)
Globe Newswire (Mon, 19-Oct 7:00 AM ET)
EyePoint Inc focuses is a clinical-stage biopharmaceutical company committed to developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases, that may reduce the frequency of follow-up care. The company's pipeline program includes i) DURAVYU: a sustained-release product candidate for retinal diseases, with the potential to provide patients with improved visual outcomes with less burden. ii) EYP-2301: early-stage program using Durasert E technology to deliver razuprotafib, a TIE-2 agonist targeting VE-PTP for vascular stability in retinal diseases like wet AMD.
Eyepoint trades on the NASDAQ stock market under the symbol EYPT.
As of November 11, 2026, EYPT stock price declined to $0.37 with 1,119,097 million shares trading.
EYPT has a beta of 4.13, meaning it tends to be more sensitive to market movements. EYPT has a correlation of 0.05 to the broad based SPY ETF.
EYPT has a market cap of $31.90 million. This is considered a Sub-Micro Cap stock.
Last quarter Eyepoint reported $507,000 in Revenue and -$1.09 earnings per share. This beat revenue expectation by $153,936 and missed earnings estimates by -$.16.
In the last 3 years, EYPT traded as high as $30.99 and as low as $.33.
The top ETF exchange traded funds that EYPT belongs to (by Net Assets): VTI, VXF, VTWO, IWM, VHT.
EYPT has underperformed the market in the last year with a return of -96.7%, while the SPY ETF gained +12.1%. In the last 3 month period, EYPT fell short of the market, returning -97.2%, while SPY returned -2.0%. However, in the most recent 2 weeks EYPT has outperformed the stock market by returning +1.9%, while SPY returned -1.8%.
EYPT support price is $.38 and resistance is $.43 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that EYPT shares will trade within this expected range on the day.
